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ABSTRACT
Disclosed is a method of detecting a concentration of a
biomarker in a human subject having or being at risk of
developing Alzheimer's disease or Mild Cognitive Impair
ment (MCI). Also disclosed is a process for detecting a
concentration of a biomarker in a human subject having or
being at risk of developing Alzheimer's disease or Mild
Cognitive Impairment (MCI) comprising (a) detecting a first
concentration of lipocalin-PDS/TTR complex in a blood
sample or urine sample from the subject, (b) determining a
second concentration of PDS/TTR complex in a blood
sample or urine sample from an unaffected individual, and
(c) comparing the first and second concentrations, wherein
a lower first concentration as compared to the second
concentration is indicative of the subject having or being at
risk of developing Alzheimer's disease.
11 Claims, 1 Drawing Sheet
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RELATED APPLICATION
This application claims priority under 35 U.S.C. 119(e) to
provisional application U.S. Ser. No. 61/572,329, filed Jul.
14, 2011 and to provisional application U.S. Ser. No. 61/566,
971, filed Dec. 5, 2011, which applications are incorporated
hereby by reference.
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FIELD OF THE INVENTION
The present invention relates to the field of detection and
monitoring of neurodegenerative disorders, including
Alzheimer's disease (AD) and mild cognitive impairment
(MCI). More particularly, the present invention relates to
proteinaceous biomarkers that can be measured in biological
fluids, which can be used to aid in the detection of neurodegenerative disorders, including Alzheimer's disease and
mild cognitive impairment.
BACKGROUND OF THE INVENTION
Previous studies suggest there is diminished transport
capacity of high molecular weight (>30 kDa) material
through choroid plexus epithelial cells in the progression of
AD. Further, it has been observed that A� 1 _42 levels are
significantly lower in serum compared to CSF because of
deposition in senile plaques (Solfrizzi, V, D'Introno, A,
Colacicco, A M, Capurso, C, Todarello, 0, et al. Circulating
biomarkers of cognitive decline and dementia Clin Chim
Acta, 2006; 364:91-112). There is an ongoing need for
methods for detecting biomarkers associated with AS and
MCI.
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SUMMARY OF THE INVENTION
In certain embodiments, the present invention provides
method of detecting a concentration of a biomarker in a
human subject having or being at risk of developing
Alzheimer's disease (AD) or Mild Cognitive Impairment
(MCI), the method comprising: (a) detecting a first concen
tration of lipocalin-PDS/TTR complex in a blood sample or
urine sample from the subject, (b) determining a second
concentration of PDS/TTR complex in a blood sample or
urine sample from an unaffected individual, and (c) com
paring the first and second concentrations, wherein a lower
first concentration as compared to the second concentration
is indicative of the subject having or being at risk of
developing AD or MCI.
In certain embodiments, the present invention provides a
method of detecting a concentration of a biomarker in a
human subject having or being at risk of developing
Alzheimer's disease (AD) or Mild Cognitive Impairment
(MCI), the method comprising: (a) detecting a concentration
of lipocalin-PDS/TTR complex in a blood sample or urine
sample from the subject, (b) comparing the concentration to
a reference value, wherein a lower concentration as compared to the reference value is indicative of the subject
having or being at risk of developing Alzheimer's disease or
MCI.
In certain embodiments, the present invention provides a
kit comprising: (a) a solid substrate; (b) a trapping binding
ligand specific for lipocalin-PDS bound to the solid sub
strate; (c) a probing binding ligand specific for TTR; (d)
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optionally, instructions for using the kit to detect PDS/TTR
in a blood sample or urine sample.
In certain embodiments, the present invention provides a
method of isolating a lipocalin-PDS/TTR complex biomarker from blood or urine comprising: (a) contacting the
blood or urine with a trapping binding ligand specific for
lipocalin-PDS to form a trapped biomarker, wherein the
trapping binding ligand specific for lipocalin-PDS is bound
to a solid substrate; (b) contacting the trapped biomarker
with a probing binding ligand that is specific for TTR to
form a probed biomarker complex; and (c) purifying the
probed biomarker complex.
In certain embodiments, the present invention provides a
process for detecting Alzheimer's disease in a human subject, the process comprising obtaining a sample of blood
from the subject, optionally preparing a sample of serum or
plasma from the sample of blood, determining the concen
tration of PDS/TTR in the sample of blood, and comparing
the concentration of PDS/TTR to a reference value.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1. The PDS/TTR complex was immunoprecipitated
from representative serum specimens from normal control
(NC) and probable AD (AD) subjects using rabbit anti-TTR
and was visualized using mouse anti-PDS. There was a
significant decrease of immunostaining for the PDS/TTR
complex in serum from AD patients (34.8±2.5% control)
compared to NC subjects (100±2.9%).
FIG. 2. Reporter operator curves for PDS/TTR and A� 1 _42
in plasma from NC (N=76) and MCI (N=45) subjects.
Improved sensitivity/specificity of the PDS/TTR complex is
reflected by the increased area under the curve (AUC) for
plasma PDS/TTR (AUC=84%) compared to an AUC of 45%
for plasma A� 1 _42 and 50% for CSF A�. Sensitivity/speci
ficity of the PDS/TTR complex were 70% compared to
sensitivity/specificity values of 52% and 44% respectively
for A� measures.
FIGS. 3A and 38. Commossie blue stained gel (A)
showing recombinant hematopoietic PDS (lane 1) and
lipocalin PDS (lane 2) and the Western blot of a second gel
probed using an anti-lipocalin PDS antibody (B).
DETAILED DESCRIPTION
Surprisingly, the inventors found that levels of the lipoca
lin-PDS/TTR complex biomarker in a blood sample were
lower in subjects with Alzheimer's disease than in non
diseased controls. The art had taught away from this finding,
in that, according to the art, levels of the biomarker in
cerebrospinal fluid were higher in subjects with Alzheimer's
Disease than in non-diseased controls.
Surprisingly, the inventors found that levels of the bio
marker in a blood sample were lower in subjects with Mild
Cognitive Impairment than in non-diseased controls. The art
had taught away from this finding, in that, according to the
art levels of the biomarker in cerebrospinal fluid were higher
in subjects with Mild Cognitive Impairment than in non
diseased controls.
In certain embodiments, the present invention provides a
concentration of a biomarker in a human subject having or
being at risk of developing Alzheimer's disease (AD) or
Mild Cognitive Impairment (MCI), the method comprising:
(a) detecting a first concentration of lipocalin-PDS/TTR
complex in a blood sample or urine sample from the subject,
(b) determining a second concentration of PDS/TTR com
plex in a blood sample or urine sample from an unaffected
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individual, and (c) comparing the first and second concen
trations, wherein a lower first concentration as compared to
the second concentration is indicative of the subject having
or being at risk of developing AD or MCI. In certain
embodiments, the blood sample is a sample of whole blood,
serum, plasma, or a subcomponent of blood. In certain
embodiments, the blood sample is a serum or plasma
sample. As used herein, the term "blood sample" includes a
whole blood sample or a subcomponent sample (e.g., a
serum sample). In certain embodiments, the lipocalin-PDS/
TTR complex is a trimer consisting of one molecule of
lipocalin-PDS and two molecules of TTR. In certain
embodiments, the lipocalin-PDS/TTR complex binds to a
trapping binding ligand specific for lipocalin-PDS but not to
a binding ligand specific for hematopoietic-PDS/TTR complex. In certain embodiments, the binding ligand is an
antibody. In certain embodiments, the lipocalin-PDS/TTR
complex is a modified lipocalin-PDS/TTR complex that
further comprises alpha and/or beta-unsaturated aldehydic
by-products of lipid peroxidation. In certain embodiments,
the lipocalin-PDS/TTR complex binds to a probing binding
ligand specific for TTR. In certain embodiments, the probing
ligand specific for TTR further comprises a label generating
a detectable signal. In certain embodiments, the label com
prises a chemical, an enzymatic, a radioactive, a fluorescent,
a luminescent, a chemiluminescent and a FRET label. In
certain embodiments, the detection of the first concentration
of lipocalin-PDS/TTR complex is by ELISA.
In certain embodiments, the present invention provides a
method of detecting a concentration of a biomarker in a
human subject having or being at risk of developing
Alzheimer's disease (AD) or Mild Cognitive Impairment
(MCI), the method comprising: (a) detecting a concentration
of lipocalin-PDS/TTR complex in a blood sample or urine
sample from the subject, (b) comparing the concentration to
a reference value, wherein a lower concentration as com
pared to the reference value is indicative of the subject
having or being at risk of developing Alzheimer's disease or
MCI.
In certain embodiments, the present invention provides a
kit comprising: (a) a solid substrate; (b) a trapping binding
ligand specific for lipocalin-PDS bound to the solid sub
strate; (c) a probing binding ligand specific for TTR; (d)
optionally, instructions for using the kit to detect PDS/TTR
in a blood sample or urine sample. In certain embodiments,
the solid substrate is a hydrocarbon polymer, glass, metal, or
gel. In certain embodiments, the solid substrate is a gelatin,
latex, polystyrene, colloidal gold, or magnetic bead. In
certain embodiments, trapping binding ligand specific for
lipocalin-PDS but not to a binding ligand specific for
hematopoietic-PDS.
In certain embodiments, the present invention provides a
method of isolating a lipocalin-PDS/TTR complex bio
marker from blood or urine comprising: (a) contacting the
blood or urine with a trapping binding ligand specific for
lipocalin-PDS to form a trapped biomarker, wherein the
trapping binding ligand specific for lipocalin-PDS is bound
to a solid substrate; (b) contacting the trapped biomarker
with a probing binding ligand that is specific for TTR to
form a probed biomarker complex; and (c) purifying the
probed biomarker complex. In certain embodiments, the
present invention provides a probed biomarker complex
isolated according to the method described above.
In certain embodiments, the present invention provides a
process for detecting Alzheimer's disease in a human subject, the process comprising obtaining a sample of blood
from the subject, preparing a sample of serum from the
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sample of blood, determining the concentration of PDS/TTR
in the sample of serum, and comparing the concentration of
PDS/TTR to a reference value. In certain embodiments,
Alzheimer's disease is detected if the concentration of
PDS/TTR is less than the reference value. In certain embodi
ments, the sample of blood is collected from the subject by
phlebotomy. In certain embodiments, the sample of serum is
prepared from the sample of blood by permitting the sample
of blood to clot and centrifuging the sample of blood. In
certain embodiments, the ELISA is an ELISA described in
U.S. Pat. No. 7,851,172. In certain embodiments, the ELISA
provides an electromagnetic signal capable of being detected
by an optical reader. In certain embodiments, the ELISA
provides an electrochemical signal capable of being detected
by an electrochemical signal detection apparatus.
A "subject" of analysis, diagnosis, or treatment is an
animal. Such animals include mammals, such as a human.
A "control" cell, tissue, sample, or subject is a cell, tissue,
sample, or subject of the same type as a test cell, tissue,
sample, or subject. The control may, for example, be exam
ined at precisely or nearly the same time the test cell, tissue,
sample, or subject is examined. The control may also, for
example, be examined at a time distant from the time at
which the test cell, tissue, sample, or subject is examined,
and the results of the examination of the control may be
recorded so that the recorded results may be compared with
results obtained by examination of a test cell, tissue, sample,
or subject. The control may also be obtained from another
source or similar source other than the test group or a test
subject, where the test sample is obtained from a subject
suspected of having a disease or disorder for which the test
is being performed.
A "test" cell, tissue, sample, or subject is one being
examined.
The use of the word "detect" and its grammatical variants
is meant to refer to measurement of the species without
quantification, whereas use of the word "determine" or
"measure" with their granimatical variants are meant to refer
to measurement of the species with quantification. The terms
"detect" and "identify" are used interchangeably herein.
Detectable Markers and Labels
According to one embodiment, the probing binding ligand
has a label generating a detectable signal. The label includes,
but not limited to, a chemical (e.g., biotin), an enzymatic
(e.g., alkaline phosphatase, peroxidase, �-galactosidase and
�-glucosidase, horseradish peroxidase), a radioactive ( e.g.,
1 1 25 and C 14), a fluorescent (e.g., fluorescein), a luminescent,
a chemiluminescent or a FRET (fluorescence resonance
energy transfer) label. Various labels and methods for label
ing binding ligands are well known in the art (Harlow and
Lane, eds., Antibodies: A Laboratory Manual (1988) Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
In certain embodiments, the probing binding ligand is an
antibody that is labeled with biotin or horseradish peroxi
dase.
As used herein, a "detectable marker" is an atom or a
molecule that permits the specific detection of a compound
comprising the marker in the presence of similar compounds
without a marker. Detectable markers include, but are not
limited to, radioactive isotopes, antigenic determinants,
enzymes, nucleic acids available for hybridization, chro
mophores, fluorophores, chemiluminescent molecules, elec
trochemically detectable molecules, and molecules that pro
vide for altered fluorescence-polarization or altered light
scattering.
The detectable labels used in the assays of the present
invention to diagnose Alzheimer's Disease, these labels are
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attached to the binding agent that is specific for PDS or TTR,
can be primary labels (where the label comprises an element
that is detected directly or that produces a directly detectable
element) or secondary labels (where the detected label binds
to a primary label, e.g., as is common in immunological
labeling). An introduction to labels, labeling procedures and
detection of labels is found in Polak and Van Noorden
(1997) Introduction to Immunocytochemistry, 2nd ed.,
Springer Verlag, N.Y. and in Haugland (1996) Handbook of
Fluorescent Probes and Research Chemicals, a combined
handbook and catalogue Published by Molecular Probes,
Inc., Eugene, Oreg. Patents that described the use of such
labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,
350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.
Primary and secondary labels can include undetected
elements as well as detected elements. Useful primary and
secondary labels in the present invention can include spec
tral labels such as green fluorescent protein, fluorescent dyes
(e.g., fluorescein and derivatives such as fluorescein isoth
iocyanate (FITC) and Oregon Green™, rhodamine and
derivatives (e.g., Texas red, tetrarhodimine isothiocynate
(TRITC), etc.), digoxigenin, biotin, phycoerythrin, AMCA,
CyDyes™, and the like), radiolabels (e.g., 3H, 1251, 35S, 14C,
32P, 33P, etc.), enzymes (e.g., horse radish peroxidase, alka
line phosphatase etc.), spectral calorimetric labels such as
colloidal gold or colored glass or plastic (e.g. polystyrene,
polypropylene, latex, etc.) beads. The label can be coupled
directly or indirectly to a component of the detection assay
(e.g., the detection reagent) according to methods well
known in the art. As indicated above, a wide variety of labels
may be used, with the choice of label depending on sensi
tivity required, ease of conjugation with the compound,
stability requirements, available instrumentation, and dis
posal provisions.
Exemplary labels that can be used include those that use:
1) chemiluminescence (using horseradish peroxidase and/or
alkaline phosphatase with substrates that produce photons as
breakdown products as described above) with kits being
available, e.g., from Molecular Probes, Amersham, Boeh
ringer-Mannheim, and Life Technologies/Gibco BRL; 2)
color production (using both horseradish peroxidase and/or
alkaline phosphatase with substrates that produce a colored
precipitate (kits available from Life Technologies/Gibco
BRL, and Boehringer-Mannheim)); 3) fluorescence using,
e.g., an enzyme such as alkaline phosphatase, together with
the substrate AttoPhos (Amersham) or other substrates that
produce fluorescent products, 4) fluorescence (e.g., using
Cy-5 (Amersham), fluorescein, and other fluorescent tags);
5) radioactivity. Other methods for labeling and detection
will be readily apparent to one skilled in the art.
Where the PDS/TTR complexes are contemplated to be
detected in a clinical setting, the labels are preferably
non-radioactive and readily detected without the necessity of
sophisticated instrumentation. In certain embodiments,
detection of the labels will yield a visible signal that is
immediately discernable upon visual inspection. One
example of detectable secondary labeling strategies uses an
antibody that recognizes PDS/TTR complexes in which the
antibody is linked to an enzyme (typically by recombinant or
covalent chemical bonding). The antibody is detected when
the enzyme reacts with its substrate, producing a detectable
product. In certain embodiments, enzymes that can be
conjugated to detection reagents of the invention include,
e.g., �-galactosidase, luciferase, horse radish peroxidase,
and alkaline phosphatase. The chemiluminescent substrate
for luciferase is luciferin. One embodiment of a fluorescent
substrate for �-galactosidase is 4-methylumbelliferyl-�-D-

5

10

15

20

25

30

35

40

45

50

55

60

65

6

galactoside. Embodiments of alkaline phosphatase sub
strates include p-nitrophenyl phosphate (pNPP), which is
detected with a spectrophotometer; 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) and fast
red/napthol AS-TR phosphate, which are detected visually;
and 4-methoxy-4-(3-phosphonophenyl)spiro[1,2-dioxetane3,2'-adamantane], which is detected with a luminometer.
Embodiments of horse radish peroxidase substrates include
2,2'azino-bis(3-ethylbenzthiazoline-6
sulfonic
acid)
(ABTS), 5-aminosalicylic acid (SAS), o-dianisidine, and
o-phenylenediamine (OPD), which are detected with a spec
trophotometer, and 3,3,5,5'-tetramethylbenzidine (TMB),
3,3' diaminobenzidine (DAB), 3-amino-9-ethylcarbazole
(AEC), and 4-chloro-1-naphthol (4ClN), which are detected
visually. Other suitable substrates are known to those skilled
in the art. The enzyme-substrate reaction and product detec
tion are performed according to standard procedures known
to those skilled in the art and kits for performing enzyme
immunoassays are available as described above.
The presence of a label can be detected by inspection, or
a detector which monitors a particular probe or probe
combination is used to detect the detection reagent label.
Typical detectors include spectrophotometers, phototubes
and photodiodes, microscopes, scintillation counters, cameras, film and the like, as well as combinations thereof.
Examples of suitable detectors are widely available from a
variety of commercial sources known to persons of skill.
Commonly, an optical image of a substrate comprising
bound labeling moieties is digitized for subsequent computer analysis.
The detection of the lipocalin-PDS/TTR complex can be
carried out by various processes well known in the art. This
detection can be carried out quantitatively or qualitatively
according to conventional procedures, e.g., using various
detectable label/substrate pairs as described in Enzyme
Immunoassay, E. T. Maggio, ed., CRC Press, Boca Raton,
Fla., 1980 and Harlow and Lane, eds. Antibodies: A Labo
ratory Manual (1988) Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y.
Where the probing binding ligand (e.g., antibody) is
labeled with alkaline phosphatase, bromochloroindolylphos
phate (BCIP), nitro blue tetrazolium (NBT) and ECF may be
used as a substrate for color developing reactions; in the case
of labeled with horseradish peroxidase, chloronaphtol,
aminoethylcarbazol, diaminobenzidine, D-luciferin, luci
genin (bis-I\Mnethylacridinium nitrate), resorufin benzyl
ether, luminol, Amplex Red reagent (10-acetyl-3,7-dihy
droxyphenoxazine, TMB (3,3,5,5-tetramethylbenzidine)
and ABTS (2,2-Azine-di[3-ethylbenzthiazoline sulfonate])
may be used as a substrate. Other label/substrate pairs
include biotin/streptavidin and luciferase/luciferin.
Binding Ligands
The present method uses two types of binding ligands,
i.e., a "trapping" (or "capturing") binding ligand and a
"probing" (or "detecting") binding ligand. As used herein,
the term "trapping binding ligand" means a binding ligand
capable of binding to the lipocalin-PDS/TTR complex of
interest in biosamples. The term "probing binding ligand"
means a binding ligand capable of binding to the lipocalinPDS/TTR complex captured by the trapping binding ligand.
In one embodiment, the binding ligand is an antibody. By
"antibody" is meant an immunoglobulin protein which is
capable of binding an antigen. Antibody as used herein is
meant to include the entire antibody as well as any antibody
fragments (e.g., F(ab')2, Fab', Fab, Fv) capable of binding
the epitope, antigen or antigenic fragment of interest. As
used herein, the term "monoclonal antibody" refers to an
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antibody obtained from a group of substantially homoge
neous antibodies, that is, an antibody group wherein the
antibodies constituting the group are homogeneous except
for naturally occurring mutants that exist in a small amount.
Monoclonal antibodies are highly specific and interact with
a single antigenic site. Furthermore, each monoclonal anti
body targets a single antigenic determinant (epitope) on an
antigen, as compared to common polyclonal antibody prepa
rations that typically contain various antibodies against
diverse antigenic determinants. In addition to their specific
ity, monoclonal antibodies are advantageous in that they are
produced from hybridoma cultures not contaminated with
other immunoglobulins.
The adjective "monoclonal" indicates a characteristic of
antibodies obtained from a substantially homogeneous
group of antibodies, and does not specify antibodies pro
duced by a particular method. For example, a monoclonal
antibody to be used in the present invention can be produced
by, for example, hybridoma methods (Kohler and Milstein,
Nature 256:495, 1975) or recombination methods (U.S. Pat.
No. 4,816,567). The monoclonal antibodies used in the
present invention can be also isolated from a phage antibody
library (Clackson et al., Nature 352:624-628, 1991; Marks et
al., J. Mo!. Biol. 222:581-597, 1991). The monoclonal
antibodies of the present invention particularly comprise
"chimeric" antibodies (immunoglobulins), wherein a part of
a heavy (H) chain and/or light (L) chain is derived from a
specific species or a specific antibody class or subclass, and
the remaining portion of the chain is derived from another
species, or another antibody class or subclass. Furthermore,
mutant antibodies and antibody fragments thereof are also
comprised in the present invention (U.S. Pat. No. 4,816,567;
Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855,
1984).
As used herein, the term "mutant antibody" refers to an
antibody comprising a variant amino acid sequence in which
one or more amino acid residues have been altered. For
example, the variable region of an antibody can be modified
to improve its biological properties, such as antigen binding.
Such modifications can be achieved by site-directed mutagenesis (see Kunkel, Proc. Natl. Acad. Sci. USA 82: 488
(1985)), PCR-based mutagenesis, cassette mutagenesis, and
the like. Such mutants comprise an amino acid sequence
which is at least 70% identical to the amino acid sequence
of a heavy or light chain variable region of the antibody,
more preferably at least 75%, even more preferably at least
80%, still more preferably at least 85%, yet more preferably
at least 90%, and most preferably at least 95% identical. As
used herein, the term "sequence identity" is defined as the
percentage of residues identical to those in the antibody's
original amino acid sequence, determined after the
sequences are aligned and gaps are appropriately introduced
to maximize the sequence identity as necessary. Methods of
producing monoclonal, polyclonal and mutant antibodies
can be found in US Patent Publication No. 2011-0135689
Al, which is incorporated by reference herein.
As used herein, the term "antibody" includes scFv,
humanized, fully human or chimeric antibodies, single
chain antibodies, diabodies, and antigen-binding fragments
of antibodies (e.g., Fab fragments). In certain embodiments,
the antibody is a human antibody or a humanized antibody.
A "humanized" antibody contains only the three CDRs
(complementarity determining regions) and sometimes a
few carefully selected "framework" residues (the non-CDR
portions of the variable regions) from each donor antibody
variable region recombinantly linked onto the corresponding
frameworks and constant regions of a human antibody
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sequence. A "fully humanized antibody" is created in a
hybridoma from mice genetically engineered to have only
human-derived antibody genes or by selection from a phage
display library of human-derived antibody genes.
As used herein, the term "antibody" includes a single
chain variable fragment (scFv), humanized, fully human or
chimeric antibodies, single-chain antibodies, diabodies, and
antigen-binding fragments of antibodies (e.g., Fab frag
ments). A scFv is a fusion protein of the variable region of
the heavy (VH) and light chains (VL) of an immunoglobulin
that is connected by means of a linker peptide. The linker is
usually short, about 10-25 amino acids in length. If flex
ibility is important, the linker will contain a significant
number of glycine. If solubility is important, serines or
theonines will be utilized in the linker. The linker may link
the amino-terminus of the VH to the carboxy-terminus of the
VD or the linker may link the carboxy-terminus of the VH to
the amino-terminus of the VL. Divalent (also called bivalent)
scFvs can be generated by linking two scFvs. For example,
a divalent scFv can be made by generating a single peptide
containing two VH and two VL regions. Alternatively, two
peptides, each containing a single VHand a single VL region
can be dimerized (also called "diabodies"). Bolliger et al.,
"Diabodies: small bivalent and bispecific antibody fragments," PNAS, July 1993, 90:6444-6448. Bivalency allows
antibodies to bind to multimeric antigens with high avidity,
and bispecificity allows the cross-linking of two antigens.
Solid Substrates
According to one embodiment, the trapping binding
ligand is bound to a solid substrate. Known materials of this
type include hydrocarbon polymers such as polystyrene and
polypropylene, glass, metals, and gels. The solid substrate
may be in the form of a dipstick, a microtiter plate, a particle
(e.g., bead), an affinity colunm and an immunoblot membrane (e.g., polyvinylidene fluoride membrane) (see U.S.
Pat. Nos. 5,143,825; 5,374,530; 4,908,305 and 5,498,551).
In certain embodiments, the solid substrate is a microtiter
plate.
According to one embodiment, the solid substrate bound
to trapping ligands is a bead such as gelatin, latex, polysty
rene, colloidal gold or a magnetic bead. The size of these
beads may be in the range of 0.3 nm to 20 µm in diameter,
and an optimal size can be selected according to the evalu
ation method to be used. For example, for macroscopic
evaluation, it is desirable to employ carriers of 0.2 to 3 µm
in diameter with which macroscopic judgment is easier.
Detection Methods and Assays
The present invention provides methods for detecting a
complex comprising PDS/TTR in a sample or in vivo. In
certain embodiments, Western blots may be used to deter
mine the presence and/or quantity of PDS/TTR in the
sample. In certain embodiments or a competitive assay (for
example, radioimmunoassay) may be used to determine the
presence and/or quantity of PDS/TTR in the sample. For
example, one can contact a sample with a binding ligand that
is specific for PDS and subsequently contact the bound
sample with a binding ligand that is specific for TTR, and
detecting the presence or the quantity of bound PDS/TTR. In
certain embodiments, the PDS/TTR is detected by means of
nuclear magnetic resonance, fluorescent capillary electro
phoresis, lateral flow devices, colorimetry, chemilumines
cence, fluorescence, western blots, microarrays, enzyme
linked immunosorbent assay (ELISA), radioHPLC, single
photon emission computed tomography (SPECT), or positron emission tomography (PET), radioimmunoassay (RIA),
immunoradiometric assay, fluoroimmunoassay, chemilumi
nescent assay, and bioluminescent assay, though several
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others are well known to those of ordinary skill. The steps
of various useful immunodetection methods have been
described in the scientific literature.
In general, the detection of immunocomplex formation is
well known in the art and may be achieved through the
application of numerous approaches. These methods are
generally based upon the detection of a label or marker, such
as any of those radioactive, fluorescent, biological and
enzymatic tags. U.S. patents concerning the use of such
labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,
350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241, each
incorporated herein by reference. Of course, one may find
additional advantages through the use of a secondary bind
ing ligand such as a second antibody and/or a biotin/avidin
ligand binding arrangement, as is known in the art.
Further methods include the detection of primary immune
complexes by a two-step approach. A second binding ligand,
such as an antibody, that has binding affinity for the PDS/
TTR is used to form secondary immune complexes, as
described above. After washing, the secondary immune
complexes are contacted with a third binding ligand or
antibody that has binding affinity for the second antibody,
again under effective conditions and for a period of time
sufficient to allow the formation of immune complexes
(tertiary immune complexes). The third ligand or antibody is
linked to a detectable label, allowing detection of the tertiary
immune complexes thus formed. This system may provide
for signal amplification if this is desired.
One method of immunodetection desi gned by Charles
Cantor uses two different antibodies. A first step biotinylated, monoclonal or polyclonal antibody is used to detect
the target antigen(s), and a second step antibody is then used
to detect the biotin attached to the complexed binding
ligand. In this method the sample to be tested is first
incubated in a solution containing the first step antibody. If
the target antigen is present, some of the antibody binds to
the antigen to form a biotinylated antibody/antigen complex.
The antibody/antigen complex is then amplified by incuba
tion in successive solutions of streptavidin (or avidin),
biotinylated DNA, and/or complementary biotinylated
DNA, with each step adding additional biotin sites to the
antibody/antigen complex. The amplification steps are
repeated until a suitable level of amplification is achieved, at
which point the sample is incubated in a solution containing
the second step antibody against biotin. This second step
antibody is labeled, as for example with an enzyme that can
be used to detect the presence of the antibody/antigen
complex by histoenzymology using a chromogen substrate.
With suitable amplification, a conjugate can be produced
which is macroscopically visible.
Another known method of immunodetection takes advan
tage of the immuno-PCR (Polymerase Chain Reaction)
methodology. The PCR method is similar to the Cantor
method up to the incubation with biotinylated DNA, how
ever, instead of using multiple rounds of streptavidin and
biotinylated DNA incubation, the DNA/biotin/streptavidin/
antibody complex is washed out with a low pH or high salt
buffer that releases the antibody. The resulting wash solution
is then used to carry out a PCR reaction with suitable
primers with appropriate controls. At least in theory, the
enormous amplification capability and specificity of PCR
can be utilized to detect a single antigen molecule.
As detailed above, immunoassays, in their most simple
and/or direct sense, are binding assays. Certain preferred
immunoassays are the various types of enzyme linked
immunosorbent assays (ELISAs) and/or radioimmunoas
says (RIA) known in the art. Immunohistochemical detec-
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tion using tissue sections is also particularly useful. How
ever, it will be readily appreciated that detection is not
limited to such techniques, and/or western blotting, dot
blotting, FACS analyses, and/or the like may also be used.
The diagnostic assay format that may be used in the
present invention could take any conventional format such
as ELISA or other platforms such as luminex or biosensors.
The present invention detects the presence of a PDS/TTR
complex. This sequence can readily be modified to facilitate
diagnostic assays, for example a tag (such as GFP) can be
added to the targeting antibody to increase sensitivity. In one
exemplary ELISA, antibodies are immobilized onto a
selected surface exhibiting protein affinity, such as a well in
a polystyrene microtiter plate. Then, a test composition
suspected of containing the PDS/TTR complex, such as a
clinical sample (e.g., a biological sample obtained from the
subject), is added to the wells. After binding and/or washing
to remove non-specifically bound immune complexes, the
bound antigen may be detected. Detection is generally
achieved by the addition of another antibody that is linked
to a detectable label. This type of ELISA is a simple
"sandwich ELISA." Detection may also be achieved by the
addition of a second antibody, followed by the addition of a
third antibody that has binding affinity for the second
antibody, with the third antibody being linked to a detectable
label.
In another exempl ary ELISA, the samples suspected of
containing the antigen are immobilized onto the well surface
and/or then contacted with binding agents. After binding
and/or washing to remove non-specifically bound immune
complexes, the bound anti-binding agents are detected.
Where the initial binding agents are linked to a detectable
label, the immune complexes may be detected directly.
Again, the immune complexes may be detected using a
second antibody that has binding affinity for the first binding
agents, with the second antibody being linked to a detectable
label.
Another ELISA in which the antigens are immobilized,
involves the use of antibody competition in the detection. In
this ELISA, labeled antibodies against an antigen are added
to the wells, allowed to bind, and/or detected by means of
their label. The amount of an antigen in an unknown sample
is then determined by mixing the sample with the labeled
antibodies against the antigen during incubation with coated
wells. The presence of an antigen in the sample acts to
reduce the amount of antibody against the antigen available
for binding to the well and thus reduces the ultimate signal.
This is also appropriate for detecting antibodies against an
antigen in an unknown sample, where the unlabeled anti
bodies bind to the antigen-coated wells and also reduces the
amount of antigen available to bind the labeled antibodies.
Irrespective of the format employed, ELISAs have certain
features in common, such as coating, incubating and bind
ing, washing to remove non-specifically bound species, and
detecting the bound immune complexes.
In coating a plate with anti-PDS or anti-TTP antibodies,
one will generally incubate the wells of the plate with a
solution of the antigen or antibodies, either overnight or for
a specified period of hours. The wells of the plate will then
be washed to remove incompletely adsorbed material. Any
remaining available surfaces of the wells are then "coated"
with a nonspecific protein that is antigenically neutral with
regard to the test antisera. These include bovine serum
albumin (BSA), casein or solutions of milk powder. The
coating allows for blocking of nonspecific adsorption sites
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on the innnobilizing surface and thus reduces the back
ground caused by nonspecific binding of antisera onto the
surface.
In ELISAs, it is probably more customary to use a
secondary or tertiary detection means rather than a direct
procedure. Thus, after binding ofa protein or antibody to the
well, coating with a non-reactive material to reduce back
ground, and washing to remove unbound material, the
immobilizing surface is contacted with the biological sample
to be tested under conditions effective to allow innnune
complex (antigen/antibody) formation. Detection of the
immune complex then requires a labeled secondary binding
ligand or antibody, and a secondary binding ligand or
antibody in conjunction with a labeled tertiary antibody or a
third binding ligand.
"Under conditions effective to allow innnune complex
(antigen/antibody) formation" means that the conditions
preferably include diluting the PDS/TTR complex with
solutions such as BSA, bovine gannna globulin (BGG) or
phosphate buffered saline (PBS)/Tween. These added agents
also tend to assist in the reduction of nonspecific back
ground.
The "suitable" conditions also mean that the incubation is
at a temperature or for a period of time sufficient to allow
effective binding. Incubation steps are typically from about
1 to 2 to 4 hours or so, at temperatures preferably on the
order of 25 ° C. to 27 ° C., or may be overnight at about 4 °
C. or so.
Following all incubation steps in an ELISA, the contacted
surface is washed so as to remove non-complexed material.
An example of a washing procedure includes washing with
a solution such as PBS/Tween, or borate buffer. Following
the formation of specific innnune complexes between the
test sample and the originally bound material, and subse
quent washing, the occurrence of even minute amounts of
immune complexes may be determined.
To provide a detecting means, the second or third anti
body will have an associated label to allow detection. This
may be an enzyme that will generate color development
upon incubating with an appropriate chromogenic substrate.
Thus, for example, one will desire to contact or incubate the
first and second innnune complex with a urease, glucose
oxidase, alkaline phosphatase or hydrogen peroxidase-con
jugated antibody for a period of time and under conditions
that favor the development of further innnune complex
formation (e.g., incubation for 2 hours at room temperature
in a PBS-containing solution such as PBS-Tween).
After incubation with the labeled antibody, and subse
quent to washing to remove unbound material, the amount
oflabel is quantified, e.g., by incubation with a chromogenic
substrate such as urea, or bromocresol purple, or 2,2'-azino
di-(3-ethyl-benzthiazoline-6-sulfonic acid (ABTS), or
H202, in the case of peroxidase as the enzyme label.
Quantification is then achieved by measuring the degree of
color generated, e.g., using a visible spectra spectrophotometer.
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ASPECTS OF THE INVENTION
Accordingly, the invention can be seen, inter alia, in the
following Aspects:
Aspect 1. A method of detecting a concentration of a
biomarker in a human subject having or being at risk of
developing Alzheimer's disease or Mild Cognitive Impair
ment (MCI), the method comprising: (a) detecting a first
concentration of lipocalin-PDS/TTR complex in a blood
sample or urine sample from the subject, (b) determining a
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second concentration of PDS/TTR complex in a blood
sample or urine sample from an unaffected individual, and
(c) comparing the first and second concentrations, wherein
a lower first concentration as compared to the second
concentration is indicative of the subject having or being at
risk of developing Alzheimer's disease.
Aspect 2. A method of detecting a concentration of a
biomarker in a human subject having or being at risk of
developing Alzheimer's disease or Mild Cognitive Impair
ment (MCI), the method comprising: (a) detecting a con
centration oflipocalin-PDS/TTR complex in a blood sample
or urine sample from the subject, (b) comparing the con
centration to a reference value, wherein a lower concentra
tion as compared to the reference value is indicative of the
subject having or being at risk of developing Alzheimer's
disease or MCI.
Aspect 3. The method of Aspect 1 or Aspect 2, wherein
the blood sample is a sample ofwhole blood, seruni, plasma,
or a subcomponent of blood.
Aspect 4. The method of any one of Aspects 1 to 3,
wherein the blood sample is a serum or plasma sample.
Aspect 5. The method of any one of Aspects 1 to 4,
wherein the lipocalin-PDS/TTR complex is a trimer con
sisting ofone molecule of lipocalin-PDS and two molecules
of TTR.
Aspect 6. The method of any one of Aspects 1 to 5,
wherein the lipocalin-PDS/TTR complex binds to a trapping
binding ligand specific for lipocalin-PDS but not to a
binding ligand specific for hematopoietic-PDS/TTR com
plex.
Aspect 7. The method of Aspect 6, wherein the binding
ligand is an antibody.
Aspect 8. The method of any one of Aspects 1 to 7,
wherein the lipocalin-PDS/TTR complex is a modified
lipocalin-PDS/TTR complex that further comprises alpha
and/or beta-unsaturated aldehydic by-products of lipid peroxidation.
Aspect 9. The method of any one of Aspects 1 to 8,
wherein the lipocalin-PDS/TTR complex binds to a probing
binding ligand specific for TTR.
Aspect 10. The method ofAspect 9, wherein the probing
ligand specific for TTR further comprises a label generating
a detectable signal.
Aspect 11. The method of Aspect 10, wherein the label
comprises a chemical, an enzymatic, a radioactive, a fluo
rescent, a luminescent, a chemiluminescent and a FRET
label.
Aspect 12. The method of any one of Aspects 1 to 11,
wherein the detection of the first concentration of lipocalin
PDS/TTR complex is by ELISA.
Aspect 13. A kit comprising (a) a solid substrate; (b) a
trapping binding ligand specific for lipocalin-PDS bound to
the solid substrate; (c) a probing binding ligand specific for
TTR; (d) optionally, instructions for using the kit to detect
PDS/TTR in a blood sample or urine sample.
Aspect 14. The kit of Aspect 13, wherein the solid
substrate is a hydrocarbon polymer, glass, metal, or gel.
Aspect 15. The kit of Aspect 13, wherein the solid
substrate is a gelatin, latex, polystyrene, colloidal gold or a
magnetic bead.
Aspect 16. The kit ofany one ofAspects 13 to 15, wherein
trapping binding ligand specific for lipocalin-PDS but not to
a binding ligand specific for hematopoietic-PDS.
Aspect 17. A method of isolating a lipocalin-PDS/TTR
complex biomarker from blood or urine comprising: (a)
contacting the blood or urine with a trapping binding ligand
specific for lipocalin-PDS to form a trapped biomarker,
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wherein the trapping binding ligand specific for lipocalin
PDS is bound to a solid substrate; (b) contacting the trapped
biomarker with a probing binding ligand that is specific for
TTR to form a probed biomarker complex; and (c) purifying
the probed biomarker complex.
Aspect 18. A probed biomarker complex isolated accord
ing to the method of Aspect 17.
Aspect 19. A process for detecting Alzheimer's disease
(AD) or Mild Cognitive Impairment (MCI) in a human
subject, the process comprising obtaining a sample of blood
from the subject, preparing a sample of serum from the
sample of blood, determining the concentration of PDS/TTR
in the sample of serum, and comparing the concentration of
PDS/TTR to a reference value.
Aspect 20. The process of Aspect 19, wherein AD or MCI
is detected if the concentration of PDS/TTR is less than the
reference value.
Aspect 21. The process of Aspect 19 or 20, wherein the
sample of blood is collected from the subject by phlebotomy.
Aspect 22. The process of any one of Aspects 19 to 21,
wherein the sample of serum is prepared from the sample of
blood by permitting the sample of blood to clot and centri
fuging the sample of blood.
Aspect 23. The process of any one of Aspects 19 to 22,
wherein the concentration of PDS/TTR in the sample of
serum is determined by ELISA.
Aspect 24. The process of any one of Aspects 19 to 23,
wherein the ELISA is an ELISA described in U.S. Pat. No.
7,851,172.
Aspect 25. The process of any one of Aspects 19 to 24,
wherein the ELISA provides an electromagnetic signal
capable of being detected by an optical reader.
Aspect 26. The process of any one of Aspects 19 to 25,
wherein the ELISA provides an electrochemical signal
capable of being detected by an electrochemical signal
detection apparatus.
The invention now will be described more fully herein
after. In particular, aspects of the invention are more fully
illustrated by the following examples, set forth to illustrate
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through aldehydic crosslinking of one molecule of brain
specific (lipocalin) PDS and one dimer of TTR delineate
between normal control (NC) subjects and patients with
mild cognitive impairment (MCI) and/or probable Alzheimer's disease (AD). To determine if the PDS/TTR complex
was present in serum of AD and NC subjects the inventors
carried out immunoprecipitation studies of serum samples
from three representative normal control (NC) subjects and
3 representative probable AD patients using rabbit anti-TTR
as the trap antibody and mouse anti-lipocalin PDS as the
probe antibody.
FIG. 1 shows the presence of a band at -55 kDa corre
sponding to 1 molecule of PDS (23 kDa) crosslinked with 1
dimer (32 kDa) of TTR in serum samples and that levels are
significantly (p<0.05) lower in probable AD patients
(35.1±2.5% control) compared to NC subjects (100±2.9%).
To further verify our hypothesis that levels of the PDS/TTR
complex decrease in serum as they increase in CSF in
MCI/AD, we used our previously described enzyme linked
immunoassay (ELISA) developed for use with CSF speci
mens (with slight modification for serum analyses) to quan
tify levels of the PDS/TTR complex in postmortem ven
tricular CSF and antemortem serum from 11 autopsyverified NC subjects and 5 MCI patients and found a strong
negative correlation between CSF and serum levels of the
complex for MCI patients (r=-0.76) but not for NC subjects
(r=0.28). Based on these data, we used a PDS/TTR ELISA
to analyze antemortem plasma specimens from 76 living NC
subjects (43M/33W) and 45 MCI (26M/19W) patients.
Subject demographic data are shown in Table 1. MCI
subjects were significantly older and showed significantly
lower MMSE scores compared to NC subjects. There was no
difference in baseline MMSE scores of NC subjects who
converted to MCI compared to those who remained controls.
Table 1 shows there was a si gnificant decrease in PDS/TTR
concentrations in MCI subjects 356.5±11.9 ng/ml) com
pared to age-matched NC subjects (621.8±34.7 ng/ml) but
no significant difference in A� 1 _42 levels.
TABLE 1

Subject demographic data, PDS/TTR and ABl-42 concentrations.
Mean± SEM
Age (y)
Sex
NC (N - 76)
MCI (N- 45)
NC - NC (n- 37)
NC - MCI (n- 29)

75.2± 0.8
79.9 0.9*
72.9 ± 1.0
77.9 ± 1.1*

43M/33W
26M/19W
19M/18W
17M/12W

Mean± SEM
MMSE
29.1± 0.1
19.7± 1.6*
29.2± 0.1
28.6± 0.4

Mean± SEM
PDS/TTR Complex
(ng/ml)
621.8±
356.5±
660.6±
451.3±

34.7
11.9*
36.7
42.1*

Mean± SEM
Al3 1 -42(pg/ml)
22.0±
20.9±
23.1±
23.1±

2.2
2.8
3.7
4.6

*p < 0.05

certain aspects of the present invention and not to be
construed as limiting thereof. The invention may, however,
be embodied in many different forms and should not be
construed as limited to the embodiments set forth herein;
rather, these embodiments are provided so that this disclo
sure will be thorough and complete, and will fully convey
the scope of the invention to those skilled in the art. As used
in this specification and the claims, the singular forms "a,"
"an," and "the" include plural referents unless the context
clearly dictates otherwise.
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Example 1
The following experiments were carried out to verify that
serum concentrations of a protein/protein complex formed

65

Reporter operator curves (ROC) (FIG. 2) for comparison
of the sensitivity/specificity for the identification of MCI
patients from NC subjects for both PDS/TTR and A� 1 _42
showed the PDS/TTR complex had an area under the curve
(AUC) of 84% (p<0.001) with a sensitivity and specificity of
70% for the identification of MCI patients from NC subjects
(cutoff=402.6 ng/ml). In contrast, A� 1 _42 results showed an
AUC of 44.6% with a sensitivity of 52% and a specificity of
44% for the same plasma samples.
The major difficulty in the development of a serum based
bioassay for AD that relies on quantification of levels of
brain specific proteins (lipocalin PDS) is the potential inter
ference by blood associated proteins specifically hematopoi
etic (glutathione-dependent) PDS and additional TTR pres-
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ent in serum. To verify that our lipocalin-specific PDS
antibody does not cross react with hematopoietic PDS, we
subjected recombinant lipocalin and hematopoietic PDS to
SDS-PAGE. FIG. 3A shows a Coomassie blue stained gel of
hematopoietic PDS in Lane 1 and lipocalin PDS in Lane 2.
FIG. 38 shows a Western blot of a separate gel stained using
the anti-lipocalin PDS antibody. These figures demonstrate
the lipocalin PDS antibody is specific for brain associated
lipocalin PDS. To further verify that the presence of
hematopoietic PDS or increased levels of TTR in serum do
not interfere with quantification of lipocalin PDS using our
ELISA we analyzed a representative serum sample alone or
in the presence of recombinant hematopoietic PDS or TTR
at concentrations between 15.75 ng/ml and 2000 ng/ml.
Table 2 shows there were no significant differences in
response of the ELISA in the presence of hematopoietic PDS
or TTR even at 2000 ng/ml.
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rology, 1984. 34(7): p. 939-44). In addition, current clinical
diagnostic methods are not foolproof with accuracies
between 65% and 90% (reviewed in Andreasen, N. and K.
Blennow, CSP biomarkers for mild cognitive impairment
and early Alzheimer's disease. Clin Neural Neurosurg,
2005. 107(3): p. 165-73; Davidsson, P. and M. Sjogren,
Proteome studies of CSP in AD patients. Mech Ageing Dev,
2006. 127(2): p. 133-7; de Leon, M. J., et al., Longitudinal
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CSP and MRI biomarkers improve the diagnosis of mild
cognitive impairment. Neurobiol Aging, 2006. 27(3): p.
394-401; Maccioni, R. B., et al., Biological markers of
Alzheimer's disease and mild cognitive impairment. Curr

Alzheimer Res, 2004. 1(4): p. 307-14) with higher rates
associated with specialized memory disorder clinics,
whereas lower rates are associated with primary care clinics.
Also, the accuracy of clinical diagnosis of AD is likely lower
during prodromal stages of the disease or for older, or poorly

TABLE 2
Mean ± SEM ELISA response (% Control) for a representative serum sample
probed witbout added hematopoietic PDS or TTR (Control) or in tbe presence of hematopoietic
PDS or TTR at concentrations from 15.75 ng/ml to 2000 ng/ml. The presence of hematopoietic
PDS or additional TTR did not significantly change tbe ELISA response at any concentration.
Concentration (ng/ml)
0
Hematopoietic
PDS
TTR

15.75

31.5

62.5

125

250

500

1000

2000

100 ± 103.3 ± 100.7 ± 99.7 ± 100.7 ± 100.7 ± 107.8 ± 95.2 ± 93.9 ±
1.2% 2.6%
4.0%
4.2%
5.3%
8.6%
5.2%
18.8% 11.7%
100 ± 119.1 ± 105.0 ± 101.7 ± 100.0 ± 110.4± 108.3 ± 109.8 ± 112.9 ±
3.5%
3.4%
5.4%
1.2% 8.2%
3.6%
4.3%
6.7%
6.5%

Sample Processing: Blood samples were drawn from
subjects. Blood samples were allowed to clot for 1 hour and
centrifuged at 3,000xg for 5 minutes to separate serum. The
serum was aliquoted into 1 ml single use aliquots and stored
at -80 ° C. in the UK-ADC tissue repository until used for
analysis.
ELISA Analyses: Quantification of PDS/TTR levels was
carried out by generally following the inventors' ELISA that
traps PDS and quantifies TTR complexed with the PDS
described in U.S. Pat. No. 7,851,172, fully incorporated by
reference herein. Samples were analyzed in triplicate and in
a blind fashion. Because of the high protein content of serum
samples SynB!ock (Serotec) was used as a blocking agent
and for dilution of trap and detection antibodies. Addition
ally, serum samples were diluted in 50 µl antigen capture
buffer (5 mM NaH2P04, 15 mM Na2P04, 2 mM EDTA, 0.4
M NaCl, 0.5% CHAPS, 0.2% bovine serum albumin and
0.4% BSA block (Serotec) (pH 7.0) for analysis. All other
parameters were as previously described. To allow compari
son across plates, a representative quality control serum
sample can be analyzed on all plates as an internal control
specimen.
Example 2
Currently, clinical diagnosis of AD is based on physical
and neurological examinations and neuropsychological
examinations coupled with neuroimaging (structural and
functional MRI, CT, PET and/or SPECT scans). Unfortu
nately, using current diagnostic criteria, AD is not defini
tively diagnosed until the disease has progressed to pro
nounced dementia (McKhann, G., et al., Clinical diagnosis

educated subjects (reviewed in (de Leon, M. J., et al.,

Longitudinal CSP and MRI biomarkers improve the diag35 nosis of mild cognitive impairment. Neurobiol Aging, 2006.
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27(3): p. 394-401). With increasing availability of poten
tially beneficial therapeutics, patients are seeking medical
intervention at earlier stages of the disease. Previous studies
suggest preclinical stages of AD may begin 20 to 30 years
before onset of clinical symptoms (reviewed Blennow, K.,
Cerebrospinal fluid protein biomarkers for Alzheimer's dis
ease. NeuroRx, 2004. 1(2): p. 213-25) and that during this

prodromal phase, neuronal degeneration and senile plaque
(SP) formation increase until a threshold is reached where
episodic memory impairment occurs, a transition between
normal aging and dementia described as amnestic mild
cognitive impairment (MCI).
Difficulties associated with diagnosis of AD has generated
considerable interest in the identification of a reliable protein
based biomarkers of AD that could aid clinicians in more
readily diagnosing AD at earlier stages before symptoms of
dementia appear (Davidsson, P. and M. Sjogren, Proteome
studies of CSP in AD patients. Mech Ageing Dev, 2006.
127(2): p. 133-7). Ideally, these biomarkers are character
istic molecules, typically proteins or protein fragments, that
are based on some fundamental feature of AD neuropathol
ogy and can be objectively measured and evaluated in a
reasonably sampled body fluid as an indicator of a patho
genic process or the response to therapeutic interventions
(reviewed in Andreasen, N. and K. Blennow, CSP biomark-

ers for mild cognitive impairment and early Alzheimer's
disease. Clin Neural Neurosurg, 2005. 107(3): p. 165-73; de
Leon, M. J., et al., Longitudinal CSP and MRI biomarkers
improve the diagnosis of mild cognitive impairment. Neu
robiol Aging, 2006. 27(3): p. 394-401; Maccioni, R. B., et
of Alzheimer's disease: report of the NIN CDS-ADRDA Work 65 al., Biological markers of Alzheimer's disease and mild
Group under the auspices of Department of Health and
cognitive impairment. Curr Alzheimer Res, 2004. 1(4): p.
Human Services Task Force on Alzheimer's Disease. Neu307-14).
60
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Current Biomarkers of AD in Blood
Although multiple potential biomarkers of AD have been
identified and studied in CSF, lumbar puncture is not a
widespread practice in primary care or geriatric clinics and
is not routinely carried out during evaluation of AD patients.
Therefore, biomarkers of AD in blood (serum or plasma)
that would allow more widely applicable, minimally inva
sive and less expensive testing of patients are critically
needed. The primary difficulty in the development of a
serum based AD diagnostic is the physiology of the blood
brain and blood-CSP barriers that typically limits the trans
fer of potentially diagnostic molecules to the blood. Addi
tionally, dilution of brain specific proteins or protein
fragments in blood make detection more difficult. Currently,
the most widely studied potential biomarkers of AD in blood
include those related to A� processing (A� 1 _42 , A� 1 _40 and
the ratio of A� 1 _42/A� 1 _40) and inflammation.
A� as a Biomarker
As observed for CSF, diminished levels of A� 1 _42 in blood
are thought to reflect deposition in SP in the brain. Comparison of blood and CSF levels of A� shows a 100-fold
decrease in plasma compared to CSF (reviewed in Solfrizzi,
V., et al., Circulating biomarkers of cognitive decline and
dementia. Clin Chim Acta, 2006. 364(1-2): p. 91-112).
Studies of the relationship between plasma A� and cognitive
impairment have been contradictory. Multiple cross sec
tional and longitudinal studies have shown evaluated plasma
A� levels in MCI and AD whereas most show no differences
between AD and NC subjects for A� 1 _40 levels. Studies of
A� 1 _42 show similar results for AD and NC subjects
although more recent longitudinal data suggest high plasma
A� 1 _42 levels were a risk factor for the development of AD.
Case control studies of MCI and NC subjects showed lower
A� 1 _42 levels in MCI patients, although they did not corre
late with disease progression or with severity of dementia.
More recent studies show no si gnificant differences in
multiple A� species between AD and control groups
although lower A� 1 _4iA�N- 42 ratios were observed for
demented (AD and non-AD) subjects compared to normal
controls (Le Bastard, N., et al., Plasma amyloid-beta forms
in Alzheimer's disease and non Alzheimer's disease patients.

Journal of Alzheimer's disease: JAD, 2010. 21(1): p. 291301). Another study suggested high baseline plasma A�42
and A�40 with decreasing A�42 levels on follow-up were
associated with more pronounced decline in multiple cognitive domains (Cosentino, S. A., et al., Plasma ss-amyloid
and cognitive decline. Archives of neurology, 2010. 67(12):
p. 1485-90).
Despite the initial promise associated with plasma A� as
a biomarker of AD, current data suggest plasma A� levels
alone do not demonstrate sufficient sensitivity or specificity
as a diagnostic biomarker ofAD. More recently, studies have
focused on quantification of levels of APP in platelets which
is cleaved following platelet activation to yield carboxy
truncated fragments of 110 or 120 to 130 kDa and suggest
a decrease in the 130 kDa/110 kDa ratio is present in MCI
and AD patients but not in NC or patients with other
neurological disorders. The APP isoform ratio correlated
with disease progression and severity and demonstrated
diagnostic sensitivities/specificities of 80-90% although the
relationship between levels of platelet specific APP and
brain alterations remains unclear.
Inflammatory Cytokines as Biomarkers of AD
Multiple studies show abnormal levels of various inflam
matory cytokines in brain regions affected in AD. However,
it remains unclear if accumulation of inflammatory mol
ecules in brain would be reflected accurately in serum/
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plasma. Studies of IL-6 in blood have been contradictory
with reports of elevations in AD or no changes. Similar
results have been observed for several other cytokines
including TNF-a and TGF-�. In more recent studies (Ray et
al., Classification and prediction of clinical Alzheimer's
diagnosis based on plasma signaling proteins. Nat Med,
2007. 13(11): p. 1359-62) using a multiplex analysis iden
tified multiple si gnaling proteins in plasma including
G-CSF, IL-la, IL-3, IL-11, GM-CSF, PDGF-BB and TNFa
that in combination, differentiated patients with AD from
age-matched NC subjects.
There is considerable need for the identification and
validation of alternative molecules that alone or in combi
nation with others would allow non-invasive tests for early
detection of AD. Based on our study demonstrating
increased levels of an aberrant protein/protein complex
consisting of 1 molecule of brain-specific (lipocalin) pros
taglandin-d-synthase (PDS; Swiss-Prot#P41222) and 1
dimer of transthyretin (TTR; Swiss-Prot#P02766) in CSF
that delineated AD from NC and DC subjects (Lovell, M. A.,
et al., An aberrant protein complex in CSP as a biomarker
of Alzheimer disease. Neurology, 2008. 70(23): p. 2212-8)
coupled with preliminary unpublished data suggesting that
cultured choroid plexus epithelial cells established from AD
and MCI subjects lose their capacity to transport large
molecules from brain compared to cultures from NC sub
jects, we hypothesized that levels of the PDS/TTR complex
would decrease in blood during disease progression and
would likely reflect diminished choroid plexus function.
Although glycosylation, phosphorylation, acetylation and
oxidative modifications have been identified for specific
isoforms of PDS in AD, PD, and ALS CSF (reviewed in
Harrington, M. G., et al., Prostaglandin D synthase isoforms
from cerebrospinal fluid vary with brain pathology. Dis
Markers, 2006. 22(1-2): p. 73-81) the association of PDS
with classical pathogenic cascades remains unclear. Similarly, TTR which is functionally active as a homotetramer
composed of 4 monomers (MW=16 kDa) arranged as a
dimer of dimers is of potential interest in AD because
mutations of the TTR gene are the most common cause of
autosomal dominant systemic amyloidoses underlying
familial amyloid polyneuropathy (FAP) that is characterized
by high abundance TTR present in �-structured fibrils.
Diminished native TTR is suggested to negatively affect A�
aggregation and alter thyroxine transport leading to neuro
degeneration (Serot, J. M., et al., Cerebrospinal fluid tran
sthyretin: aging and late onset Alzheimer's disease. J Neural
Neurosurg Psychiatry, 1997. 63(4): p. 506-8). Although no
mutations of TTR have been identified in AD, TTR overexpression is neuroprotective in AD animal models (Stein, T.
D., et al., Neutralization of transthyretin reverses the neu
roprotective effects of secreted amyloid precursor protein
(APP) in APPSW mice resulting in tau phosphorylation and
loss of hippocampal neurons: support for the amyloid
hypothesis. J Neurosci, 2004. 24(35): p. 7707-17).

Considerable research effort has been directed at the study
oflevels ofA� 1 _42 and A� 1 _40 or ratios ofthe two as potential
diagnostic biomarkers of AD. Unfortunately, the studies are
been somewhat contradictory leaving a need for evaluation
of additional novel serum/plasma biomarkers of the disease.
The aims described in this proposal are innovative in that
they are directed at the potential diagnostic efficacy of a
novel biomarker of disease that appears to have improved
sensitivity/specificity compared to measures of A�. In addition, the proposed studies will evaluate potential synergies

US 9,835,621 B2
19

between our novel biomarker and more established markers
to evaluate potential enhancement of diagnostic efficacy of
the individual measures.
Immunoprecipitation studies of serum samples from 3
representative NC subjects and 3 probable AD patients using
mouse anti-PDS as the trap antibody and rabbit anti-TTR as
the probe antibody, identified a band at-55 kDa correspond
ing to 1 molecule of PDS (23 kDa) crosslinked with 1 dimer
(32 kDa) of TTR in serum. Levels of the complex were
significantly (p<0.05) lower in probable AD patients
(35.1±2.5% control) compared to NC subjects (100±2.9%).
To further verify our hypothesis that levels of the PDS/TTR
complex decrease in serum as they increase in CSF in
MCI/AD, we used our previously described enzyme linked
immunoassay (ELISA) developed for use with CSF speci
mens (Lovell, M. A., et al., An aberrant protein complex in
CSP as a biomarker ofAlzheimer disease. Neurology, 2008.
70(23): p. 2212-8) (with slight modification for serum
analyses) to quantify levels of the PDS/TTR complex in
postmortem ventricular CSF and antemortem serum from 11
autopsy-verified NC subjects and 5 MCI patients and found
a strong negative correlation between CSF and serum levels
of the complex for MCI patients (r=-0.76) but not for NC
subjects (r=0.28). To allow comparison of results of our
PDS/TTR measures with the more established marker A�,
we tested paired serum/plasma samples from probable AD
and NC subjects and found that plasma concentrations of the
complex were higher than those observed in serum. Based
on these data we used our PDS/TTR ELISA to analyze
antemortem plasma specimens from 76 living NC subjects
(43M/ 33W) and 45 MCI (26M/19W) patients. Subject
demographic data are shown in Table 3. MCI subjects were
significantly older and showed significantly lower MMSE
scores compared to NC subjects. There was no difference in
baseline MMSE scores of NC subjects who converted to
MCI compared to those who remained controls. Table 3
shows there was a significant decrease in PDS/TTR con
centrations in MCI subjects 356.5±11.9 ng/ml) compared to
age-matched NC subjects (621.8±34.7 ng/ml) but no sig
nificant difference in A�1 _42 levels.
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with immunizing peptides showed the lipocalin PDS anti
body is specific for brain associated lipocalin PDS (data not
shown). Analysis of a representative plasma sample alone or
with recombinant hematopoietic PDS or TTR added at
concentrations between 15.75 ng/ml and 2000 ng/ml showed
no significant difference in response of the ELISA.
Example 3
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To test if serum PDS/TTR complex concentrations
decrease in the same person following conversion to MCI by
analyzing pre- and post-conversion serum specimens from
NC subjects who transitioned from normal to MCI or AD
compared to results obtained for serum samples from control
subjects who remained cognitively normal after a comparable follow-up period. We analyzed plasma samples
obtained from 28 MCI patients before and after conversion
from NC status to MCI and showed a significant 31.6±8.5%
decrease in levels of PDS/TTR for MCI patients following
conversion compared to 43 NC subjects who remained
cognitively normal after a comparable follow-up period.
Table 4 shows mean±SEM percent change in PDS/TTR
concentrations, MMSE scores and A� levels and shows a
significantly more pronounced change in PDS/TTR concentrations in MCI patients compared to changes in MMSE or
A� levels suggesting levels of the complex may be a more
sensitive indicator of disease progression. In addition, based
on PDS/TTR concentrations measured in initial plasma
draws we identified a subset of 10 NC subjects with unusu
ally low PDS/TTR concentrations who remained cognitively
normal at the second plasma draw but who showed signifi
cantly diminished scores on logical memory tasks at subse
quent draws.

TABLE 3
Subject demographic data, PDS/TTR and ABl-42 concentrations.
Mean±SEM
Age (y)
Sex
NC (N - 76)
MCI (N- 45)
NC-NC (n - 37)
NC-MCI (n - 29)

75.2±0.8
79.9 0.9*
72.9±1.0
77.9±1.1*

43M/33W
26M/19W
19M/18W
17M/12W

Mean±SEM
MMSE
29.1±0.1
19.7±1.6*
29.2±0.1
28.6±0.4

Mean±SEM
PDS/TTR Complex Mean±SEM
Al3 1 -42 (pg/ml)
(ng/ml)
621.8±34.7
356.5 ±11.9*
660.6 ± 36.7
451.3 ±42.1*

22.0±2.2
20.9±2.8
23.1 ± 3.7
23.1 ± 4.6

*p < 0.05

Reporter operator curves (ROC) (FIG. 2) for comparison
of the sensitivity/specificity for the identification of MCI
patients from NC subjects for both PDS/TTR and A�1 _42
showed the PDS/TTR complex had an area under the curve
(AUC) of 84% (p<0.001) with a sensitivity and specificity of
70% for the identification of MCI patients from NC subjects
(cutoff=402.6 ng/ml). In contrast, A�1 _42 results showed an
AUC of 44.6% with a sensitivity of 52% and a specificity of
44% for the same plasma samples.
Potential interference by blood associated proteins, spe
cifically hematopoietic (glutathione-dependent) PDS and
additional TTR present in blood are potential analytical
difficulties. Western blot analysis using antibodies blocked

TABLE 4

55

Mean±SEM % Mean±SEM % Mean±SEM %
Change PDS/TTR Change in Aj3 1 42 Change in MMSE

60

NC-NC
NC-MCI

±

9.0±5.3
-22.3 ±2.9*

3.1±1.3
23.3 ±13.4

-1.2±0.01
-6.3 ±1.5*

Mean SEM % change in PDS/TTR concentration is significantly larger than changes in
MMSE
A� 1-42 levels.
*p < 0.05.
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Overall, the data suggest that quantification of levels of
the PDS/TTR complex in plasma may be effective in the
identification of AD subjects including those early in disease
progression (MCI patients). Early identification of AD
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would allow pharmacologic interventions that could delay
cognitive decline associated with AD and improve the
quality of life for those subjects. The proposed test could
also be used as a screen to better identify subjects for
in�l�si?� in clinical trials of potential therapeutics thereby
m1mm1zmg the number of subjects needed to insure a
sufficient number of subjects convert to AD during the trial.
In our preliminary studies, the PDS/TTR complex was
reliable, reproducible, and provided the necessary sensitiv
ity/specificity for the identification of subjects early in
disease progression (MCI).
Every reference cited herein is incorporated fully by
reference. To the extent that there is any conflict between the
t�aching of any reference and that of the instant specifica
tion, the teaching of the instant specification shall control.
Many modifications and other embodiments of the inven
tion will come to mind to one skilled in the art to which this
invention pertains having the benefit of the teachings pre
sented in the foregoing description. Therefore, it is to be
understood that the invention is not to be limited to the
specific embodiments disclosed and that modifications and
other embodiments are intended to be included within the
scope of the appended claims. Although specific terms are
employed herein, they are used in a generic and descriptive
sense only and not for purposes of limitation.
Although the foregoing specification and examples fully
.
disclose and enable the present invention, they are not
intended to limit the scope of the invention, which is defined
by the claims appended hereto.
All publications, patents and patent applications are incorporated herein by reference. While in the foregoing speci
fication this invention has been described in relation to
certain embodiments thereof, and many details have been set
forth for purposes of illustration, it will be apparent to those
skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described
herein may be varied considerably without departing from
the basic principles of the invention.
The use of the terms "a" and "an" and "the" and similar
referents in the context of describing the invention are to be
construed to cover both the singular and the plural, unless
otherwise indicated herein or clearly contradicted by con
text. The terms "comprising," "having," "including," and
"containing" are to be construed as open-ended terms (i.e.,
meaning "including, but not limited to") unless otherwise
�oted. Recitation of ranges of values herein are merely
11:tended to serve as a shorthand method of referring indi
vidually to each separate value falling within the range,
unless otherwise indicated herein, and each separate value is
incorporated into the specification as if it were individually
recited herein. All methods described herein can be per
formed in any suitable order unless otherwise indicated
herein or otherwise clearly contradicted by context. The use
of any and all examples, or exempl ary language (e.g., "such
as") provided herein, is intended merely to better illuminate
the )nvent)on and does not pose a limitation on the scope of
the mvent10n unless otherwise claimed. No language in the
specifi
_ cation should be construed as indicating any non
clmmed element as essential to the practice of the invention.
Embodiments of this invention are described herein
including the best mode known to the inventors for carryin�
out the invention. Variations of those embodiments may
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become
_ apparent to those of ordinary skill in the art upon
re�dmg t�e foregoing description. The inventors expect
skil�ed artisan� to employ such variations as appropriate, and
the mventors mtend for the invention to be practiced other
�ise t�an �s specifically described herein. Accordingly, this
mvent10n mcludes all modifications and equivalents of the
subject matter recited in the claims appended hereto as
permitted by applicable law. Moreover, any combination of
the above-described elements in all possible variations
thereof is encompassed by the invention unless otherwise
indicated herein or otherwise clearly contradicted by con
text.
The invention claimed is:
1. A method of detecting lipocalin-prostaglandin-d-syn
thase/transthyretin (PDS/TTR) biomarker complex in a
human subject suspected of having Alzheimer's disease or
mild cognitive impairment, comprising:
(i) obtaining a blood sample or urine sample from the
human subject suspected of having Alzheimer's disease
or mild cognitive impairment; and
(ii) detecting the lipocalin-prostaglandin-d-synthase/tran
sthyretin (PDS/TTR) complex in the blood sample or
urine sample from the subject by contacting the smnple
with a trapping binding ligand that is an anti-lipocalin
PDS antibody followed by contacting the smnple from
the subject with a probing binding ligand that is an
anti-TTR antibody to obtain a lipocalin-PDS/TTR
complex.
2. The method of claim 1, wherein the anti-lipocalin PDS
antibody is a mouse anti-lipocalin-PDS antibody, and the
anti-TTR antibody is a rabbit anti-TTR antibody.
3. The method of claim 1, wherein the blood sample is a
smnple of whole blood, serum, plasma, or a subcomponent
of blood.
4. The method of claim 1, wherein the blood sample is a
serum or plasma sample.
5. The method of claim 1, wherein the probing binding
ligand specific for TTR further comprises a label generating
a detectable signal.
6. The method of claim 5, wherein the label comprises a
chemical, an enzymatic, a radioactive, a fluorescent, a
luminescent, a chemiluminescent or a Fluorescence Reso
nance Energy Transfer (FRET) label.
7. The method of claim 1, wherein the detection of the
lipocalin-PDS/TTR complex is by enzyme-linked immu
nosorbent assay (ELISA).
8. The method of claim 1, wherein the detection of the
lipocalin-PDS/TTR complex is by enzyme-linked immu
nosorbent assay (ELISA), and wherein the lipocalin-PDS/
TTR biomarker complex is a trimer consisting of one
molecule of lipocalin-PDS and two molecules of TTR.
9. The method of claim 2, wherein the rabbit anti-TTR
antibody further comprises a label generating a detectable
signal.
10. The method of claim 9, wherein the label comprises
a chemical, an enzymatic, a radioactive, a fluorescent, a
luminescent, a chemiluminescent or a Fluorescence Reso
nance Energy Transfer (FRET) label.
11. The method of claim 1, and further comprising deter
mining whether there is a lower concentration of lipocalin
PDS/TTR complex in the smnple than in a normal control.

* * * * *

